News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Insider Information

​​​​​​​Epigenomics AG: Resignation of the Chairman of the Supervisory Board Heino von Prondzynski

Epigenomics AG / Key word(s): Personnel​​​​​​​Epigenomics AG: Resignation of the Chairman of the Supervisory Board Heino von Prondzynski 27-Jan-2023 / 14:16 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.The issuer is solely responsible for the content […]

Read more

​​​​​​​Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022

Epigenomics AG / Key word(s): Change in Forecast​​​​​​​Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022 21-Dec-2022 / 11:18 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.The issuer is solely responsible for […]

Read more

Epigenomics Releases Performance Data on Next Generation Test

Epigenomics AG / Key word(s): Study results/MiscellaneousEpigenomics Releases Performance Data on Next Generation Test 14-Dec-2022 / 05:11 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Epigenomics […]

Read more

Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs

Epigenomics AG / Key word(s): Change in Forecast/ForecastEpigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs 19-Sep-2022 / 10:36 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS – a service of EQS Group […]

Read more

Epigenomics AG: Capital reduction planned at a ratio of 4 : 1

Epigenomics AG / Key word(s): Corporate Action/AGM/EGM Epigenomics AG: Capital reduction planned at a ratio of 4 : 1 09-Sep-2022 / 19:19 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content […]

Read more

Epigenomics AG: Reduction of principal amount of planned mandatory convertible bond to up to EUR 16.5 million and of conversion price to EUR 1.10 per share

Epigenomics AG / Key word(s): Issue of Debt/Corporate ActionEpigenomics AG: Reduction of principal amount of planned mandatory convertible bond to up to EUR 16.5 million and of conversion price to EUR 1.10 per share 20-Aug-2021 / 10:41 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by […]

Read more